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Abstract
 
As well as classically defined switched immunoglobulin isotype-expressing B cells, memory B cells
are now thought to include IgM-expressing cells and memory cells that lack B cell lineage
markers, such as B220 or CD19. We set out to compare the relative importance of memory B
cell subsets with an established flow cytometry method to identify antigen-specific cells. After
 
immunization with PE, we could detect B220
 
 
 
 and, as reported previously, B220
 
 
 
 antigen-bind-
 
ing cells (McHeyzer-Williams, L.J., M. Cool, and M.G. McHeyzer-Williams. 2001. 
 
J. Immunol
 
.
167:1393–1405). The B220
 
 
 
PE
 
 
 
 cells bore few markers typical of B cells, but resembled myeloid
 
cells. Further analysis of the antigen-binding characteristics of these cells showed that, upon
 
immunization with two fluorescent proteins, the B220
 
 
 
 cells could bind both. Furthermore,
 
this subpopulation was detected in RAG1
 
 
 
/
 
 
 
 mice after transfer of anti-PE mouse serum. These
data strongly suggest that these cells capture serum Ig, via Fc receptors, and thus appear antigen-
specific. Investigation of these antigen-capturing cells in a variety of knockout mice indicates that
 
they bind monomeric IgG in an Fc
 
 
 
R1 (CD64)–dependent manner. We find no evidence of a
B220
 
 
 
 memory B cell population that is not explicable by antigen-capturing cells, and warn that
 
care must be taken when using antigen-specificity or surface IgG as an indicator of B cell memory.
Key words: immunological memory • Fc receptors • phycoerythrin • antigen-binding cell • 
B220
 
Introduction
 
Progress in understanding the mechanisms of B cell mem-
ory (the phenomenon of enhanced recall antibody re-
 
sponses) has been hampered by the lack of a definitive
phenotypic marker for memory B cells. Indeed, much con-
fusion has arisen recently concerning the composition of
the memory B cell compartment. Although, classically, B
cell memory has been attributed to an IgM
 
 
 
IgD
 
 
 
 subset of
resting B cells (1–3), recent studies have found the hall-
marks of memory (somatic hypermutation and enhanced
responses to antigen) within B cells of every immunoglob-
ulin class (4, 5). In addition, a novel memory B cell popula-
tion, devoid of B cell lineage markers such as CD19 and
B220, has been reported to be the predominant memory B
cell population in mice (6–8). These B220
 
 
 
 memory B
cells were identified by their ability to bind antigen.
As well as antigen-specific memory B cells, immuniza-
tion generates other cell populations that contribute to the
memory state. First, there is a population of nonlymphoid
 
cells, the follicular dendritic cells (FDC),
 
*
 
 that bind anti-
gen–antibody complexes to their surface via Fc receptors
(FcRs) or complement receptors (CRs) and can store anti-
gen for long periods after immunization (9, 10). Second,
long-lived plasma cells in the bone marrow and gut lamina
propria produce antibodies, independently of antigen, for
several months after immunization (11, 12). The antibody
secreted into the serum by plasma cells acts as a first line of
defense when the antigen reenters the body, not only by
neutralizing, opsonizing, or initiating the complement cas-
cade but also by activating APCs (13). The binding of anti-
gen–antibody complexes to FcRs, and possibly CRs, on
APCs is an activating event, as well as a means of increasing
antigen uptake (14). Together, the changes that character-
ize the immune state mean that B cell memory must be
considered an emergent property of a system, rather than a
quality attributable to a single, long-lived, expanded clone
of cells.
 
We set out to further characterize B cells and non–B
accessory cells that contribute to enhanced recall antibody
responses to antigen. To track antigen-specific memory B
cells, we immunized mice with the fluorescent protein PE,
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Abbreviations used in this paper:
 
 ACC, antigen-capturing cells; APC, al-
 
lophycocyanin; APCs, antigen-presenting cells; 
 
 
 
2
 
m, 
 
 
 
2 
 
microglobulin;
BrdU, 5-bromo-2
 
 
 
-deoxyuridine; CR, complement receptor; DC, den-
dritic cell; FcR, Fc receptor; FDC, follicular DC; NP, nitrophenyl; QM,
quasi-monoclonal.T
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a method developed by Hayakawa and coworkers (15) and
used by the Rajewsky lab to study memory B cells (1, 16).
In mice and rats, immunization with haptens, such as ni-
trophenyl (NP), or with fluorescent moieties, such as
FITC or PE, can be used to detect antigen-specific B cells
by FACS
 
®
 
, immunofluorescence, or immunohistochemis-
try. However, the interpretation of this type of data re-
quires awareness that not all antigen-binding cells are
memory B cells. For example, cells that enter the plasma
cell differentiation pathway may still bind antigen until the
terminal stages of differentiation, although they begin to
lose a number of B cell lineage markers; e.g., B220, CD19,
and MHC class II (17). Also, FDC and other cells express-
ing FcR or CR bind immune complexes in vivo that are
readily detectable when antigen is added ex vivo for
FACS
 
®
 
 analysis (18).
After immunization with PE, we identified two popula-
tions of PE-binding cells based on B220 staining: B220
 
 
 
and B220
 
 
 
 cells. Despite extensive investigations, we could
find no evidence that the B220
 
 
 
 cells were memory B
cells. This paper provides strong evidence that the B cell
lineage–negative memory cell described by others might in
fact be an unusual myeloid lineage cell (6–8). By absorbing
serum IgG in an Fc
 
 
 
R1 (CD64)–dependent manner, these
cells appear antigen-specific upon analysis, and might regu-
late aspects of B cell memory.
 
Materials and Methods
 
Animals.
 
All mice were maintained under specific pathogen-
free conditions. C57BL/6, RAG1
 
 
 
/
 
 
 
, 
 
 
 
2 
 
microglobulin (
 
 
 
2
 
m)
 
 
 
/
 
 
 
,
FcR 
 
 
 
 chain
 
 
 
/
 
 
 
 (19), and quasi-monoclonal (QM) mice were
bred and maintained in the Science Faculty Animal Facility of the
University of Edinburgh. RAG1
 
 
 
/
 
 
 
 mice were bred and main-
tained in isolators. C1q
 
 
 
/
 
 
 
 (20), Fc
 
 
 
RIII
 
 
 
/
 
 
 
 (21), and FcR 
 
 
 
chain
 
 
 
/
 
 
 
 (19) mice were provided by Dr. M. Botto (Imperial
College School of Medicine, London, UK). QM mice (22) were
donated by Dr. P. Lane (University of Birmingham, Birming-
ham, UK) with the permission of Dr. M. Wabl (University of
California, San Francisco, San Francisco, CA). 
 
 
 
2
 
m
 
 
 
/
 
 
 
 mice were
provided by Prof. R. Maizels (Institute of Cell, Animal, and Pop-
ulation Biology, University of Edinburgh, Edinburgh, UK). Ani-
mals were aged 6–10 wk when immunized and were sex- and
age-matched as closely as possible.
 
Antigens.
 
R-PE and allophycocyanin (APC) were both ob-
tained from Prozyme. PE and BSA (Sigma-Aldrich) were cou-
pled to NP by reacting with 40 or 200 
 
 
 
g, respectively, of NP-
O-suc (Biosearch Technologies Inc.) in dimethyl formamide
(Sigma-Aldrich), in 0.2 M carbonate/bicarbonate buffered to pH
9. In each case, hapten conjugates were dialyzed against PBS to
remove free hapten.
 
Immunizations.
 
50- or 100-
 
 
 
g soluble PE or APC was in-
jected intraperitoneally in 200 
 
 
 
l PBS plus 10
 
9
 
 killed 
 
Bordetella
pertussis
 
 (Calbiochem). Boost doses were as primary challenge, ei-
ther with or without 
 
B. pertussis
 
.
 
Cell Preparations.
 
Single cell suspensions of spleen were pre-
pared in HANKS-buffered saline (Sigma-Aldrich) plus 5% FCS
by pressing through nylon gauze. Red blood cells were removed
by hypotonic lysis. 100–200 
 
 
 
l of peripheral blood was collected
from mice tails into heparinized tubes, diluted in PBS, and centri-
 
fuged over Lympholyte-M (Cedarlane Laboratories) to remove
red blood cells. Bone marrow cells were flushed from both fe-
murs with HANKS buffer.
 
Intravenous Transfer of Anti-PE Serum.
 
C57BL/6 mice immu-
nized with PE, 
 
 
 
8 wk, earlier were boosted with 50 
 
 
 
g PE, bled
7 d later, and the serum was collected. Recipient C57BL/6 or
RAG1
 
 
 
/
 
 
 
 mice were injected intravenously with 200 
 
 
 
l of se-
rum and another 200 
 
 
 
l after 24 h and killed 18 h later.
 
Flow Cytometry Analysis.
 
To detect NP, PE, or APC-binding
cells, up to 10
 
6
 
 cells were stained in 100 
 
 
 
l FACS
 
®
 
 buffer (PBS 
 
 
 
1% newborn calf serum), with 2.5 
 
 
 
g/ml NP-PE, 2.5 
 
 
 
g/ml PE,
or 10 
 
 
 
g/ml APC, 15 min on ice, and washed immediately in
FACS
 
®
 
 buffer. The following mAbs were purchased from BD
Biosciences: anti-B220/RA3-6B2-FITC, PE, PerCP; anti–
CD21/CD35/7G6-FITC; anti–CD138/281-2-biotin; anti–
CD43/S7-biotin and anti–CD11c/N418-FITC; anti-CD1/1B1-
biotin. F480-FITC and anti–CD11b/M1/70-FITC were
purchased from Sigma-Aldrich. 33ID and DEC-205 were pro-
vided by Dr. S. Howie (University of Edinburgh, Edinburgh,
UK). Polyclonal goat anti–mouse IgM-biotin and IgG-FITC
were purchased from Southern Biotechnology Associates, Inc.
Anti-CD45-FITC was the gift of Dr. V. Tybulevich (National
Institute for Medical Research, London, UK). Anti–CD4/
GK1.5-FITC, anti–CD8/53.6.72-biotin, anti–MHC class II/
M5114-biotin, anti–MHC class I/M1/42-biotin, anti–Id(QM)/
R2.248-biotin, and anti–CD40/FGK-45 were produced in
house (protein G purification from tissue culture supernatants).
Purified antibodies were conjugated to biotin by reacting with 75
 
 
 
g succinimidyl-6-(biotinamido) hexanoate (EZ-Link™ NHS-
LC-Biotin; Pierce Chemical Co.) according to manufacturer’s in-
structions. Secondary reagents used are as follows: streptavidin-PE
(Calbiochem), streptavidin-FITC (Sigma-Aldrich), streptavidin-
cy5 (Amersham Biosciences), and mouse (Fab) anti–rat IgG-
FITC (Jackson ImmunoResearch Laboratories). Cells were incu-
bated with primary reagents in FACS
 
®
 
 buffer for 20 min on ice,
washed three times, and, where required, incubated with second-
ary reagents for 20 min on ice. Cells were resuspended in PBS for
flow cytometry analysis on a FACScalibur™ (Becton Dickinson).
Where necessary, dead cells were excluded by adding 7-amino-
actinomycin D to 1 
 
 
 
g/ml (Sigma-Aldrich) 60 s before analysis.
 
BrdU-labeling Assay.
 
Mice were given 0.8 mg/ml 5-bromo-
2
 
 
 
-deoxyuridine (BrdU; Sigma-Aldrich) in their drinking water
for 4 d and killed. The BrdU drinking water was made fresh each
day and protected from the light. Splenocytes and bone marrow
were harvested and single cell suspensions were made. 10
 
6
 
 cells
were stained with PE as for FACS
 
®
 
, washed in PBS, and resus-
pended in 0.5 ml 0.15 M NaCl. While gently vortexing, 1.2 ml
of ice-cold 95% ethanol was added, cells were washed in PBS,
and resuspended in 1 ml 1% paraformaldehyde/0.01% Tween 20
for 20–30 min at room temperature. Cells were centrifuged and
resuspended in DNase I (Sigma-Aldrich) solution (50 U/ml
DNase I and 4.2 mM MgCl
 
2
 
/0.15 M NaCl, pH 5) for 10 min at
room temperature, washed in PBS, and resuspended in 10 
 
 
 
l
anti–BrdU-FITC (BD Biosciences) for 30 min at room tempera-
ture. Cells were washed in PBS before being analyzed by
FACS
 
®
 
.
 
Results
 
A Novel B220
 
 
 
 Antigen-binding Compartment.
 
C57BL/6
mice were immunized intraperitoneally with PE, using as
an adjuvant heat-killed 
 
B. pertussis
 
, which enhances bothT
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IgG1 and IgG2a antibody responses (23). 2 wk after im-
munization, the spleen, where the primary response ini-
tiates after intraperitoneal immunization, and bone marrow
were removed. We were interested in bone marrow be-
cause this is the major site of antibody production during
the memory phase of the response. Cell suspensions were
stained with PE and for the B cell differentiation marker
B220, and analyzed by flow cytometry (Fig. 1 A). Back-
ground PE staining in unimmunized mice is minimal in
the B220
 
 
 
 compartment (0.00–0.02%) with more variable
levels on the B220
 
 
 
 compartment (0.01–0.08%). As de-
scribed previously (1, 15), a population of B220
 
 
 
 PE-bind-
ing cells is clearly visible in the spleen at the day-14 time
point (0.54% of total spleen). At this early time point, these
are probably mostly PE-specific, affinity-matured, germi-
nal center B cells, although there will also be some mem-
ory cells and plasma cells in the spleen. We also detected a
distinct second population of PE-binding cells in the
spleen, which were B220
 
 
 
 (0.25%). In previous PE immu-
nization studies (1), these cells were not described, pre-
sumably because they did not gate on B220 or CD19. In
the bone marrow, there is also a B220
 
 
 
PE
 
 
 
 population
Figure 1. Two populations of
antigen-binding cells. (A) Spleen
and bone marrow cells from an
unimmunized mouse and a PE-
immunized mouse, day 14, were
stained for PE-binding activity
and B220 expression. Plots are
gated on live white cells. In each
case, bone marrow and spleen
are from the same mouse. Per-
centages of B220 PE  and
B220 PE populations (box
gates) of total white cells are
shown above each gate. There is
minimal background PE stain-
ing in the unimmunized mouse.
Results shown are representa-
tive of at least 20 mice analyzed
during this work. (B) B220 PE 
and B220 PE  cells were back-
gated to show their forward scat-
ter (FSC), x axis, and side scatter
(SSC), y axis. Both plots are
from the same mouse and are
representative of at least five
mice. (C) B220 PE  cells were
FACS®-sorted from the bone
marrow of PE-immunized mice.
Cytospins of these sorted cells
(top and middle) and of whole
bone marrow (bottom) were
stained with hematoxylin and eosin. B220 PE  cells are most similar in size and morphology to monocytes; they are unlike lymphocytes (L), or PMNs
(N). All three panels are shown at the same magnification using 100  objective.
 
Figure 2.
 
Maintenance of PE-binding cell populations over time. At
various times after PE immunization, up to 180 d, the percentages of
B220
 
 
 
PE
 
 
 
 cells in the spleen and B220
 
 
 
PE
 
 
 
 cells in the spleen and bone
marrow were measured by FACS
 
®
 
 (as in Fig. 1 A). Each point plotted
represents a single mouse.T
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(0.54% of total white cells), which is the major PE-binding
cell type at this site. We could also identify these
B220
 
 
 
PE
 
 
 
 cells in the peripheral blood after immuniza-
tion (unpublished data).
 
Antigen-binding Capacity, Light-scatter, and Morphological
Properties.
 
Fig. 1 A shows that B220
 
 
 
 and B220
 
  PE-
binding populations differ in their antigen binding capacity.
The splenic B220  compartment appears heterogeneous in
this respect, with a wide range of PE staining intensities.
This would be expected of an oligoclonal B cell population
at different stages of activation, which would have variable
avidity for antigen. By comparison, the PE B220  com-
partment in the spleen and bone marrow is very homoge-
nous, the range of PE staining intensities is narrow and of
intermediate level (Fig. 1 A). Although in individual mice
we found that the PE staining intensity of B220  cells is al-
Figure 3. Surface phenotype of B220  and B220 
antigen-binding cells in spleen and bone marrow.
Three-color FACS® analysis was used to assess the ex-
pression of various markers on B220 PE  cells and
B220 PE  from PE-immunized mice 2–5 wk after pri-
mary immunization. Cell populations were stained and
gated as in Fig. 1 A. Panels show staining for the indi-
cated marker of the gated population. Expression on the
gated population is shown in bold (solid line) against
that of either the whole spleen or bone marrow (dotted
line). In the two bottom panels (MHC class I and
CD1), the staining of the B220 PE  populations (gray-
shaded profile) versus whole spleen or bone marrow
cells (solid line) is shown. In each panel, the spleen and
bone marrow stainings are from the same mouse. Pro-
files are representative of at least three mice analyzed.T
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ways within a narrow range, between mice this range often
varied greatly, by as much as a log (unpublished data).
Fig. 1 B shows that B220 PE  cells from the spleen fall
within the normal lymphocyte forward scatter/side scatter
gate, as expected of B cells, whereas B220 PE  cells have
higher side scatter (SSC). This indicates that these cells are
more granular than normal lymphocytes. As the normal
lymphocyte gate excludes the B220  antigen-binding cells,
this may explain why these cells have not been described in
the original flow cytometry studies of antigen-specific B
cells (1). Cytospins of FACS®-sorted B220 PE  bone mar-
row cells were stained with hemotoxylin and eosin dyes.
Fig. 1 C shows that B220 PE  cells are mononuclear and
larger than lymphocytes. Their cytoplasm is slightly granu-
lar and the nucleus often appears indented, which is charac-
teristic of monocytes. These cells do not resemble classical
lymphocytes or granulocytes; overall, their morphology is
best described as monocytic. When cytospins were stained
for  -naphthyl acetate esterase, only a minority ( 10%) of
the cells were positive (unpublished data), however, not all
macrophage populations are positive for this enzyme.
B220  Antigen-binding Cells Are Maintained for Long Peri-
ods. The frequencies of both B220  and B220  antigen-
binding cell types were measured at several time points af-
ter immunization. In the spleen, B220 PE  cells peak in
frequency at around 3 wk and decline rapidly thereafter.
By 8 wk, they were undetectable above background in
the B220  population (Fig. 2). B220 PE  cells also
reached their maximal frequency at  3 wk, but their
numbers fell only slightly and they stabilized at an average
of 0.4% in the spleen and 0.6% in the bone marrow.
These frequencies were maintained in the spleen and
bone marrow for at least 6 mo after immunization (Fig.
2). That this novel cell population is maintained long into
the quiescent memory phase, and is found in the major
sites of recall and long-lived antibody responses (the
spleen and the bone marrow, respectively), indicated that
it might be involved in B cell memory.
B220  Antigen-binding Cells Are IgG  but Lack Other B
Lineage Markers. Phenotypic analysis by FACS® showed
that B220 PE  cells have IgG antibodies on their surface
but lack IgM (Fig. 3). In addition, they lacked expression of
the B cell coreceptors CD19 and CD21, whereas B220 
PE  cells in the spleen expressed both these receptors.
Plasma cells are also known to down-regulate these recep-
tors, however, the B220 PE  cells did not express the
plasma cell marker syndecan-1 (CD138). In addition, they
were negative for expression of the T cell lineage markers
CD4 and CD8. However, they were found to express low
to intermediate levels of the integrins CD11b (Mac-1) and
CD11c (Fig. 3). They expressed CD40, but lacked other
dendritic cell (DC) markers, such as 33D1 and DEC-205.
They exhibited variable, low to intermediate levels of F4-
80 staining, a characteristic macrophage marker. Although
lacking the B220 CD45R isoform, B220 PE  cells do ex-
press CD45, as shown by staining with mAb YW62.3,
which recognizes all CD45 isoforms. The expression of this
pan-leukocyte marker indicates this cell is likely to be of
hematopoietic rather than stromal cell origin. The adhesion
molecule CD43 is absent on mature B cells, however,
B220 PE  cells express high levels of CD43. B220 PE 
cells were found to express variable levels of MHC class II,
high levels of MHC class I, and low to intermediate levels
of the nonclassical MHC molecule CD1.
Figure 3 (continued)T
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The B220 PE  Compartment Does Not Expand in Re-
sponse Antigen. One defining functional characteristic of
memory cells is their ability to proliferate and differentiate
rapidly into effector cells in response to antigen. To see if
this was true of the B220 PE  cells, we immunized mice
with PE (   B. pertussis), and 10 wk later, rechallenged
them with soluble PE alone. Assaying the PE-binding cells
over a 9-d period after boost, we could see no expansion of
B220 PE  cells (Fig. 4). The percentage of B220 PE 
cells remained roughly the same from day 0 (pre-boost) to
days 4 and 9 after boost. At 10 wk after immunization, we
were unable to detect B220 PE  memory B cells in the
spleen (or elsewhere), and it is noteworthy that the
B220 PE  cells did not give rise to B220 PE  cells upon
restimulation. Also of interest is the fact that on day 9, the
level of PE binding is significantly higher than at days 0 or
4, indicating an increase in the amount of specific immu-
noglobulin on the surface of the cells.
B220  Antigen-binding Cells Can Capture More Than One
Antigen. Given their phenotype, we suspected that the
B220 PE  cells were not B cells, but rather an accessory
cell that binds antibody (and therefore antigen) via FcR or
CR. If this were the case, the cells should be able to cap-
ture more than one antigen. On the other hand, a memory
B cell should be mono-specific. To test this, we immu-
nized mice with two distinct fluorescent proteins at the
same time. Mice were immunized with either PE alone,
APC (allophycocyanin, a blue fluorphore) alone, or both
PE and APC together. After 4 wk, spleen and bone mar-
row cells were stained with both PE and APC. In double-
immunized mice, all B220 PE  cells are also APC  and,
conversely, all B220 APC  cells are also PE  (Fig. 5 A).
PE  cells from PE single-immunized mice do not also
bind APC, and conversely, APC  cells from APC single-
immunized mice do not also bind PE. This shows there is
no antigenic cross-reactivity between these two fluores-
cent proteins, and no nonspecific binding. We concluded
from this experiment that the B220  antigen-binding cells
in the spleen and bone marrow are not mono-specific and,
thus, cannot be memory B cells. The most probable expla-
nation is that these cells, through binding-secreted immu-
Figure 4. Response of B220 PE  cells to secondary immunization.
Mice were primed with PE and rechallenged with PE in the absence of
adjuvant 6 wk later. 0, 4, and 9 d after immunization, mice were killed,
and spleen and bone marrow stained for B220 and PE-binding. The size
of the gated B220 PE  population is shown as percentage of total cells.
Two mice were taken at each time point. Plots show staining from a sin-
gle mouse from each group, both mice gave similar results.
Figure 5. Dual specificity of B220 PE  cells. (A) Spleen and bone
marrow were harvested from three C57Bl/6 mice immunized 4 wk be-
fore with: (a) APC alone; (b) PE alone; and (c) APC and PE together.
Cells were stained with anti–CD19-FITC, PE, and APC, and analyzed by
FACS®. Plots show PE (x axis) and APC (y axis) binding of the CD19 
population. This experiment was repeated twice with the same result. (B)
QM mice were immunized and boosted with APC. 2 wk later, spleens
were harvested and analyzed by three-color flow cytometry for CD19 ex-
pression, NP binding, and APC binding. In each plot, CD19 is on the x
axis. CD19 NP  (R2) are back-gated to show their APC binding activ-
ity and CD19 APC  (R3) cells are back-gated to show their NP binding
activity. Data shown are from one mouse and are representative of three
mice analyzed.T
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noglobulin, can capture whichever antigen the animal has
been immunized with.
We also looked at dual specificity of the B220 CD19 
antigen-binding cells in the spleen and bone marrow of
NP-specific VH-knockin QM mice (22), in which Cas-
calho et al. (8) have described B220 NP  cells and mem-
ory B cells. Thus, QM mice were immunized with APC,
and stained with and NP–PE. Fig. 5 B shows that all
CD19 APC  cells were also NP , and almost all
B220 NP  cells are APC . We conclude that the
CD19 NP  cells in QM mice correspond to the CD19 /
B220  antigen-binding cells in APC and PE-immunized
normal mice described previously.
Transfer of Anti-PE Sera. To show that B220 PE  cells
bind antigen by first capturing Ig from the serum, we asked
if antigen-specific binding could be transferred with se-
rum. 200  l of serum from a PE-immunized mouse 4–7 d
after secondary challenge was transferred intravenously
into nonimmunized wild-type and RAG1 /  mice. The
RAG1 /  mice have no circulating antibody and no PE-
binding cells in the spleen or bone marrow before serum
transfer (unpublished data). 36 h after transfer of immune
serum, the spleen and bone marrow were harvested and
analyzed. A B220 PE  population can be detected in both
groups of mice (Fig. 6). The frequencies of this population
in both mice are comparable to the corresponding popula-
tion in PE-immunized mice (Fig. 1). As RAG1 /  mice
lack mature lymphocytes, this experiment also indicates
that B220 PE  cells are not derived from the lymphoid
lineage. This experiment also shows that the development
of these antigen-capturing cells (ACC) is not dependent on
factors produced by T or B cells, unlike FDCs, for exam-
ple, which do not develop in the absence of B cells (24).
Mechanism of Immunoglobulin Binding. There are four
known FcRs that can bind IgG: Fc RI, Fc RIII, Fc RII,
and the neonatal FcR. Fc RII is expressed on a variety of
cell types, however, incubation with a blocking mAb
against this receptor (24G2) had no effect on antigen bind-
ing by the B220 PE  subset (unpublished data). The in-
volvement of the other receptors was investigated using a
panel of gene-targeted mice. Neonatal FcR is a member of
the MHC class I protein family and forms a heterodimer
with  2m (25), therefore,  2m /  mice do not express this
receptor (26). After PE immunization, we found  2m / 
mice to have normal frequencies of B220 PE  cells in the
spleen and bone marrow (Fig. 7 A). Fc R1 (CD64) and
Fc RIII (CD16) are multimeric receptors that use the same
signaling subunit, the FcR common   chain. Fc RIII has
low affinity for monomeric IgG, but binds complexed anti-
body with high avidity, and it is expressed only on myeloid
cells. Fc RIII /  mice were found to have B220 PE  cells
in the spleen and bone marrow (Fig. 7 B). Binding via
complement, activated in the classical pathway, was ruled
by finding B220 PE  cells in C1q /  mice after immuni-
zation (Fig. 7 B). Fc R1 /  mice were not available, and
thus, to examine the involvement of Fc R1, we examined
mice that lacked the FcR common   chain. These mice
cannot express Fc RIII, Fc RI, nor the high affinity IgE
receptor Fc R1 (19). Fc RI is the highest affinity IgG re-
ceptor and can bind monomeric IgG (27). FcR   chain  / 
mice were found to have a complete absence of B220 PE 
cells in both the spleen and bone marrow (Fig. 7 C). These
mice do have a normal population of B220 PE  cells, in-
dicating that B cell responses in these mice are not signifi-
cantly affected, as reported previously (18). It is unlikely
that the absence of B220 PE  cells is due to a defect in
anti-PE antibody production (we found it to be normal in
the Fc R1 /  mice [unpublished data]). As we have al-
ready ruled out a requirement for Fc RIII, the absence of
B220 PE  cells in the FcR   chain  /  mice is probably
due to the lack of Fc RI. We did not have access to an
mAb that specifically recognizes mouse Fc R1, and there-
Figure 6. Transfer of PE-binding activity to
RAG1 /  using sera from PE-immunized mice. Un-
immunized C57BL/6 or RAG1 /  mice were given
two intravenous injections of 200  l of sera from a
PE-immunized and boosted mouse. The second injec-
tion was given 24 h after the first, and mice were killed
18 h later. A profile from a positive control PE-immu-
nized mouse is shown for comparison. Spleen and
bone marrow were analyzed by FACS® for B220 and
PE binding.T
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fore, were unable to confirm directly that this receptor is
expressed on B220 PE  cells. Our FACS® data (Fig. 3) in-
dicated that the B220 PE  cells bind IgG, however, we
have not tested for surface binding of IgE. It is possible that
Fc R1 and IgE may also contribute to the antigen-captur-
ing activity of B220 PE  cells.
B220 PE  ACC Are Rapidly Dividing. By flow cy-
tometry, a B220 PE  antigen-capturing population can
only be detected after ex vivo staining with PE. Therefore,
it is most likely that in vivo, these cells are binding mono-
meric immunoglobulin rather than Ig–PE immune com-
plexes. In agreement with this, Fc R1 is known to bind
monomeric IgG with high affinity (27). As the antigen-
capturing population is maintained for long periods after
immunization, we sought to determine whether these were
long-lived cells like FDCs (in which case the IgG on their
surface may have been captured early in the response), or
self-replenishing cells (in which case the IgG on their sur-
face will have been acquired recently). The incorporation
of the thymidine analogue BrdU can be used as an indica-
tor of cells that have undergone DNA replication in vivo
(28). At various times after PE immunization, mice were
given a 4-d pulse of BrdU in their drinking water. Spleen
and bone marrow were harvested and analyzed, by flow
cytometry, for BrdU content and PE binding. At 3 wk af-
ter immunization,  90% of PE  cells in the spleen and
bone marrow were found to be BrdU  after 4-d labeling
(Fig. 8). 8 wk after immunization, 55–77% of the
B220 PE  cells, in spleen or BM, are dividing over a 4-d
period. At 12 wk, the splenic B220 PE  cells continue to
divide rapidly (mean of 82% labeled over the 4-d BrdU
pulse). In the bone marrow, there is apparently a gradual
decline in the level of turnover, and after 6 mo, only 50%
of PE  cells in the bone marrow become BrdU  during
the 4-d labeling period. However, this is still a high level of
turnover. By way of comparison, 12 wk after immuniza-
tion, only 9% of splenic B cells incorporated BrdU in 4 d.
The high level of turnover within the PE-capturing popu-
lation implies that these cells are continually generated
from precursors and cannot retain IgG on their surface for
long periods of time, as FDCs do. Instead, they must con-
centrate on their surface a sample of the IgG in current cir-
culation at the time they are generated.
Discussion
We have found a population of B220  antigen-binding
IgG  cells that appears within the first 2 wk of immuniza-
tion and is maintained at stable frequencies for long peri-
ods. Despite initial impressions, these cells are not mem-
ory B cells and not even B cells, but masquerade as
memory B cells by binding serum IgG to their surface.
The most conclusive evidence to this effect is that when
mice were immunized with two distinct fluorescent anti-
gens, the B220  cells bind both equally well. Further-
more, these cells appear in RAG1 /  mice after the trans-
Figure 7. B220 PE  cells do
not appear after immunization of
FcR    chain knockout mice.
Various knockout mouse lines
were immunized with PE.
Spleen and bone marrow were
harvested 3–5 wk later and ana-
lyzed by FACS® for B220 ex-
pression and PE-binding activity.
(A–C) The mean percentage of
B220 PE  cells ( SD, n   3).
(A) B220 PE  cells in  2m / 
and C57BL/6 mice. (B)
B220 PE  cells in C1q / ,
Fc RIII / , and C57BL/6. (C)
B220 PE  cells in FcR  
chain /  and C57BL6. (D) Rep-
resentative FACS® plots from
FcR   chain  /  and C57BL/6,
spleen and bone marrow.T
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fer of hyper-immune serum. We can find no evidence of a
lineage marker negative B cell population that fulfils the
criteria of memory cells. At about the time we began this
work, two groups published reports of novel B220 
memory B cells (6–8). In light of results presented here, it
is necessary to reexamine these reports in detail, to estab-
lish whether some, or even all, of the properties of the
novel B220  memory cell compartment are attributable to
the ACC we have described here.
The initial paper from Cascalho et al. (8) describes a
population of B220 CD19 IgG  B cells in the peripheral
blood of QM mice, in which the majority of B cells are
specific for the hapten NP. This is due to a targeted inser-
tion of VH186.2, which can pair with   light chains (the
mice were bred to a K /  J H
 /  background). The
B220 CD19 IgG  B cells do not express IgM, CD19, nor
syndecan-1 (CD138, a plasma cell marker). These cells
were defined as memory B cells after the V genes amplified
and sequenced from sorted cells were found to contain so-
matic mutations (a hallmark of memory cells). Is this con-
clusive evidence of their identity as memory B cells? It is
notoriously easy to obtain falsely positive results with re-
verse transcriptase–PCR amplification; for instance, a 1%
contamination with plasma cells (B220lo cells containing
large amounts of Ig mRNA) might well yield very good
VH sequences. In our own experiments, after FACS® sort-
ing the B220 PE  and B220 PE  populations to greater
than 95% purity (with B cell contamination of  1% in
the latter) we were able to amplify equivalent IgG1 re-
verse transcriptase–PCR products (unpublished data), even
though we now know that the B220 PE  cells are not of
the B cell lineage. We also found a B220 NP-binding
population in QM mice but noted that all these cells would
become double-labeled with APC after immunization with
this fluorophore.
In the more extensive studies of B220  memory B cells
by McHeyzer-Williams and coworkers, normal mice were
immunized with NP-KLH, and antigen-specific cells were
detected by an NP–fluorophore conjugate (6). After pri-
mary immunization with 400  g of antigen in Ribi ad-
juvant, followed 8 wk later by an identical secondary
challenge, they were able to detect a B220 NP IgD  (syn-
decan-1 ) population in the spleen and bone marrow. In a
more recent work, the splenic population was detectable
during the primary response (7). This novel B cell com-
partment can be divided into two subsets, one expressing
IgG and the other IgE. The conclusion that these B220 
antigen-binding cells represent the major memory B cell
population, rather than a non-B cell binding antigen, is
based on three key pieces of evidence: (a) they have hyper-
mutated V  genes; (b) they transfer memory to naive hosts;
and (c) they do not appear after transfer of immune sera.
Regarding the hyper-mutation data, by sorting single cells,
the aforementioned problem of plasma cell contamination
is avoided. However, no indication is given about the ac-
curacy of this sorting procedure and the efficiency of am-
plification of Ig gene products. Worryingly, a positive V 
PCR product is obtained from only 15% of samples; given
the preponderance of   in the primary NP response in B6
mice, we would expect a much larger number to be posi-
tive. In the adoptive transfer experiments, FACS®-sorted
NP B220  or NP B220  populations were transferred to-
gether with helper T cells into RAG1 /  mice. When an-
tigen was cotransferred, both B220  and B220  cells were
found to give rise to B220 , B220 , and B220 /  syn-
decan-1  antigen-binding populations, and antibody re-
sponses. This implies a bi-directional lineage relationship
between B220  and B220  antigen-binding cells. In our
own experiments, secondary challenge of mice carrying
PE-binding B220  cells does not give rise to B220  cells
(Fig. 4). In the experiments of McHeyzer-Williams (6, 7),
unlike B220  memory B cells, the B220  cells do not sur-
vive transfer at all in the absence of antigen. It is argued
that the appearance of B220  antigen-binding cells after the
transfer of B220  memory cells, T cell help, and antigen
indicates that the B220  cells must be derived from B220 
memory B cells. The data we present here suggest an alter-
native explanation, that IgG antibody produced after adop-
tive transfer of B220  memory B cells, helper T cells, and
antigen binds, via Fc Rs, to a subset of B220  myeloid
cells. Also, other workers have found no evidence of
B220  memory cells. In experiments designed to test if
Figure 8. Turnover of B220 PE  and the B220 PE  cells. BrdU in-
corporation into dividing cells over a 4-d period was assessed 3, 8, 12, and
27 wk after PE immunization. Spleen and bone marrow were analyzed by
FACS® for PE binding and BrdU incorporation. B220  cells in the spleen
were also analyzed for BrdU incorporation at 3, 8, and 12 wk. (A) Typi-
cal BrdU/PE FACS® profile (from bone marrow at 8 wk). (B) Percentage
of PE  cells in the spleen and bone marrow that are BrdU  after 4-d la-
beling, at various times after immunization. Each point represents an indi-
vidual mouse with a line showing the mean value of each group.T
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long-lived plasma cells required, or were responsive to,
antigen, Radbruch and colleagues separated B220  and
B220  bone marrow populations from OVA-immunized
mice and transferred them, with T cell help, into naive
hosts (11, 29). The B220  cells behaved like memory cells,
giving rise to serum anti-OVA titers only after antigen
boost. In contrast, in the recipients of B220  bone marrow,
serum titers of anti-OVA IgG steadily rose due to the trans-
fer of long-lived plasma cells. This antibody production
happened in the absence of added antigen and even its ad-
dition did not cause any increase in the specific IgG titers.
This argues against the existence of a B220  memory cell in
the bone marrow.
The demonstration by McHeyzer-Williams et al. (6) that
the B220 NP  population does not appear in RAG1 / 
mice upon transfer of immune sera, arguing against passive
binding of serum Ig by these cells, is directly contrary to
the data shown here (transfer of anti-PE serum into
RAG1 /  mice allowed detection of B220 PE  cells in
the spleen and bone marrow; Fig. 6). The explanation for
this difference almost certainly lies in the amounts of serum
transferred. To detect the B220 PE  cells, we had to trans-
fer 200  l of sera twice; if we transferred anything  100  l
of hyper-immune serum, we could not detect any PE-
binding cells. McHeyzer-Williams et al. (6) transferred only
50  l of sera. In this respect, it is interesting to note that in
their initial paper (6), the B220 NP  cells can only be de-
tected after secondary challenge; this may be because levels
and/or affinity of NP-specific Ig in the serum were too low
to allow detection in the primary response.
Although we find no evidence of B220  memory cells,
we have identified in vivo an unusual antigen-binding cell.
We prefer the term ACC because these cells have the ca-
pacity to capture antigen as it enters the body by virtue of
the immunoglobulin bound to FcR on their surface.
Clearly, there is a vast literature on cells that bind IgG cy-
tophilically (30–32); the cells we define are not obviously
macrophages and can efficiently sample the circulating
pool of IgG. The lack of ACC in the FcR   chain / 
mice indicates that serum Ig binds to FcR that contains the
FcR   chain. Using the specific knockouts, we have ex-
cluded a role for the low affinity Fc RIII; therefore, it
must be one, or both, of the high affinity Ig receptors,
Fc R1 or Fc R1, which is involved. It is interesting in
this context that the B220  memory cells described by
McHeyzer-Williams et al. (6) can be split into IgG and IgE
expressors. The FcR   chain is reported to be restricted to
myeloid cells and it has not been found on T or B cells
(33). Fc R1 can bind monomeric, soluble Ig. The rate of
BrdU incorporation by ACC tells us that they are a rapidly
turning over and, therefore, unlike long-lived FDC, the Ig
on their surface must have been acquired recently. Given
that the antibodies in the serum have a half-life of only a
few days (34), the long-lived presence of B220 PE  ACC
must be due to prolonged production of anti-PE Ig by
long-lived plasma cells. Interestingly, the two tissues where
we find ACC, the spleen and bone marrow, are the two
sites where long-lived plasma cells are found (11, 12, 35),
thus, ACC are ideally situated to pick up and concentrate
Ig on their surface.
Although we have identified Fc R1 as the mechanism
by which ACC capture antigen, it is not clear what their
function might be. As ACC bind IgG but not IgM, they
can only capture the immunizing antigen late in the pri-
mary response or in the secondary response, when IgG is
produced. A variety of functions have been attributed to
Fc R1 and Fc R1, which must all be considered possible
functions of ACC. These fall into two broad categories: ef-
fector functions or immuno-regulatory functions. Fc R1 is
expressed by macrophages, monocytes, and DCs, and can
be up-regulated by IFN-  (36, 37); on neutrophils and
eosinophils, IFN-  induces de novo expression. In these
cells, Fc RI can trigger phagocytosis of IgG-opsonized
particles and cytotoxic activity against IgG-coated targets;
i.e., antibody-dependent cell cytotoxicity. Fc R1 may also
have an important role in regulating adaptive immune re-
sponses, as antigen targeted to this receptor is processed and
presented on MHC class I and MHC class II by DCs in
vitro (38, 39). In vivo, there are effects of the FcR   chain
knockout on T cell priming (40) and marginally on
T-dependent antibody production, with one paper show-
ing no difference across all IgG subclass responses (18) and
another showing (at lower Ag doses) a twofold reduction
(40). We also found normal numbers of antigen-specific
plasma cells in these mice (unpublished data). Therefore, it
seems unlikely that the inability to detect PE-binding ACC
in the FcR   chain /  mice is related to defects in antigen-
specific antibody production.
Secreted Ig has effects on the induction and regulation of
adaptive T and B cell responses (41), although the mecha-
nisms are ill-defined. Cross-linking by antigen of the serum
Ig bound to FcR on ACC could initiate or participate in
one of the following effects: (a) down-regulation of inflam-
matory T/B cell responses; (b) initiation of secondary T
cell responses; (c) presentation of FDC antigen depots to T
cells; and (d) enhancement of plasma cell survival. Fc R1
does not bind all IgG subclasses with equivalent affinity; in
mice, the hierarchy (in the monomeric form) is IgG2a   
IgG1   IgG2b   IgG3 (42). Mouse IgG2a is the most in-
flammatory IgG isotype due to its propensity to fix com-
plement and interact with FcR on effector cells (43). Iso-
type switching to IgG2a is promoted by the Th1 cytokine
IFN- , and IgG2a production is associated with Th1-type
responses; e.g., antiviral responses. In binding IgG2a, ACC
could mediate negative feedback control of inflammatory
responses. For instance, B cell–deficient mice ( MT) ex-
hibit exacerbated inflammatory responses to Leishmania
donovani (44) and Schistosomiasis mansoni infections (45), as
well as a more severe form of experimental autoimmune
encephalomyelitis (46, 47). Transfer of serum can protect
the  MT mice from this tissue-damaging response (44).
Finally, ACC might be involved in memory responses
due to their ability to capture antigen as soon as it enters
the body. ACC might present antigen directly to T cells,
and they may be able to retrieve antigen from the surface of
FDC. Both functions could impinge on the maintenance ofT
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memory CD4 T cells, which is impaired in  MT mice
(48) and possibly in FcR   chain  /  mice (unpublished
data). We have also considered that ACC might, by secret-
ing trophic cytokines, aid the survival of long-lived plasma
cells in the bone marrow or elsewhere; however, we have
found no abnormalities in long-term specific antibody pro-
duction in FcR   chain  /  mice.
Although the function of ACC is not yet clear, we show
that they are the major antigen-binding non–B cell popula-
tion in the spleen and the bone marrow. As we can find no
evidence for a B220  memory B cell population after im-
munization with PE, we conclude that ACC may in the
past have been mistaken for memory B cells. Finding this
cell demonstrates that the combination of antigen-binding
activity and surface IgG expression cannot be reliably used
to identify memory B cells. Care must be taken to exclude
these cells, in the ways outlined here, not only when study-
ing memory but also receptor editing, allelic exclusion, and
any other analysis of BCR specificity/identity.
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